Start your patients with
postpartum depression
(PPD) on
ZURZUVAE with
these 3 steps

Explore resources around patient support, financial assistance, and copay support for ZURZUVAE® (zuranolone)

ZURZUVAE is covered for ~95% of insured Commercial and Medicaid
patients* and is covered by the 3 largest pharmacy benefit managers

Source: Managed Markets Insight & Technology, LLC database as of November 2025.

*Supernus Pharmaceuticals and Biogen do not endorse any particular plan. This is not a promise or guarantee by Supernus Pharmaceuticals and Biogen concerning coverage and/or availability of the product for any particular patient. Because formularies change and many health plans offer more than one formulary, it is important to check directly with the health plan to confirm coverage for individuals.

Send the prescription, the patient’s medical and pharmacy insurance information, and the patient’s demographics to the appropriate specialty pharmacy within the ZURZUVAE network

  • Create the prior authorization (PA) in CoverMyMeds® or use the health plan’s specific PA form. It is essential to complete all fields in the PA and submit the PA and all required supporting documentation to the health plan
  • Verify specialty pharmacy options or requirements with your patient's insurance 
to prevent potential delays in the process

When prescribing ZURZUVAE in your electronic health
record, refer to this table for helpful tips.
Download the full dosing and prescribing guide

Where can I get ZURZUVAE?

ZURZUVAE is available through the following specialty pharmacy network†; it is not available through retail pharmacies.

  • Accredo®
  • Accredo® Honolulu
  • Alto Pharmacy®
  • CVS Specialty®

  • Special Care Pharmacy Services‡
  • Walmart Specialty Pharmacy
Get ZURZUVAE specialty pharmacy contact information

†Specialty pharmacy network as of August 2025. Individual patient insurance coverage is not guaranteed. A patient's insurance coverage may require the use of a specific specialty pharmacy. 

‡Special Care Pharmacy Services is for Puerto Rico residents only.

Ensure the PA is complete and accurate prior to submitting to the health plan, with the following information included

  • ICD-10 code
    The correct ICD-10 code for patients diagnosed with PPD is F53.0.1§ Not using the correct code may result in delays
  • All patient, provider, and visit information

If required by health plan, also include:

  • Previous treatments and length of trial
  • Relevant chart notes/documentation that support the treatment decision for ZURZUVAE

§This code is presented for informational purposes only. It is not a statement, promise, or guarantee concerning coverage and/or levels of reimbursement, payment, or charge and is not intended as a recommendation to increase or maximize reimbursement by any payer. It is the responsibility of the healthcare provider to determine the appropriate code(s) for diagnosis or service provided to his or her patient.

For questions or more information on patient support services, contact your ZURZUVAE representative or call
1-844-987-9882

Alert your patient that they will receive at least 2 calls from the
specialty pharmacy to confirm their insurance, contact, and
shipping information

It is important your patient answers all calls†
from the specialty pharmacy

  • Please note that the specialty pharmacy will contact the patient twice: once to confirm their insurance and contact information and a second time after insurance approval to coordinate shipment (see step 3)
  • The specialty pharmacy cannot dispense ZURZUVAE prescriptions until they have verified the delivery address for shipment and reviewed appropriate financial assistance options with the patient
  • Consider suggesting that your patient add the specialty pharmacy phone number as a contact in their phone to avoid the calls going to spam

†Note: If a patient has previously opted in, the specialty pharmacy may text the patient instead of calling if the specialty pharmacy has the ability to do so.

Does ZURZUVAE have a patient support program?

ZURZUVAE For You is a patient support program that is available to help your patients as they navigate their treatment journey.

ZURZUVAE For You provides services to women, including Support Coordinators who are able to provide information on ZURZUVAE, financial assistance programs, and if prescribed, getting medication.

Does ZURZUVAE offer a copay savings card 
for my patients?

Financial assistance programs, such as the ZURZUVAE Savings Card Program,‡ may be available to eligible adult patients with PPD who have been prescribed ZURZUVAE.

Eligible adult patients with commercial insurance may pay as little as a $0 copay for their ZURZUVAE prescription.§

‡Financial assistance for eligible patients under the ZURZUVAE Savings Card Program will be applied directly by the specialty pharmacy filling the prescription. Restrictions apply. For full terms and conditions, please see ZurzuvaeForYouTermsAndConditions.com.

§Only commercially insured patients with a valid, on-label ZURZUVAE prescription are eligible. Additional restrictions apply.

For questions or more information on patient support services, contact your ZURZUVAE representative or call
1-844-987-9882

Once the plan approves ZURZUVAE for your patient, the
specialty pharmacy will ship the medication to their
preferred address

The specialty pharmacy
will contact your patient
again to confirm shipment
and delivery information

ZURZUVAE prior authorization denials may be successfully appealed

  • If your patient is denied a second time, potential steps may be required to obtain coverage. Contact your ZURZUVAE representative to discuss potential options for your patient

For questions or more information on patient support services, contact your ZURZUVAE representative or call
1-844-987-9882
Download the full guide to getting patients started on ZURZUVAE
Sign up to receive more information about ZURZUVAE or request live support
Request information

References: 1. ICD-10-CM Tabular List of Diseases and Injuries. Centers for Medicare & Medicaid Services. Last updated October 1, 2025. https://www.cms.gov/medicare/coding-billing/icd-10-codes. Accessed December 1, 2025.

INDICATION

ZURZUVAE® (zuranolone) is indicated for the treatment of postpartum depression (PPD) in adults.

 

IMPORTANT SAFETY INFORMATION

WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES

ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects.

Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE.

 

WARNINGS AND PRECAUTIONS

Impaired Ability to Drive or Engage in Other Potentially Hazardous Activities

  • ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects
  • Advise patients not to drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness, such as operating machinery, until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence or the degree of driving impairment caused by ZURZUVAE

Central Nervous System Depressant Effects

  • ZURZUVAE can cause CNS depressant effects such as somnolence and confusion
  • Somnolence developed in 36% of patients who received ZURZUVAE (50 mg) and in 6% of patients who received placebo daily. Some ZURZUVAE-treated patients developed confusional state. One of these cases was severe, and was also associated with somnolence, dizziness, and gait disturbance
  • A higher percentage of ZURZUVAE-treated patients, compared to placebo-treated patients, experienced somnolence, dizziness, or confusion that required dosage reduction, interruption, or discontinuation
  • Because ZURZUVAE can cause CNS depressant effects, patients may be at higher risk of falls
  • Other CNS depressants such as alcohol, benzodiazepines, opioids, tricyclic antidepressants, or drugs that increase zuranolone concentration, may increase impairment of psychomotor performance or CNS depressant effects such as somnolence, cognitive impairment, and the risk of respiratory depression in ZURZUVAE-treated patients
  • To reduce the risk of CNS depressant effects and/or mitigate CNS depressant effects that occurs with ZURZUVAE treatment:
    • If patients develop CNS depressant effects, consider dosage reduction or discontinuation of ZURZUVAE
    • If use with another CNS depressant is unavoidable, consider dosage reduction
    • Reduce the ZURZUVAE dosage in patients taking strong CYP3A4 inhibitors

Suicidal Thoughts and Behavior

  • In pooled analyses of placebo-controlled trials of chronically administered antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with major depressive disorder (MDD)
  • ZURZUVAE does not directly affect monoaminergic systems. Consider changing the therapeutic regimen, including discontinuing ZURZUVAE, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors

Embryo-fetal Toxicity

  • Based on findings from animal studies, ZURZUVAE may cause fetal harm when administered to a pregnant woman
  • Advise a pregnant woman of the potential risk to an infant exposed to ZURZUVAE in utero. Advise females of reproductive potential to use effective contraception during treatment with ZURZUVAE and for one week after the final dose
 

ADVERSE REACTIONS

  • The most common adverse reactions (≥5% and greater than placebo) in ZURZUVAE-treated patients were somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection
 

DRUG INTERACTIONS

CNS Depressant Drugs and Alcohol

  • Caution should be used when ZURZUVAE is administered in combination with other CNS drugs or alcohol. If use with another CNS depressant is unavoidable, consider dosage reduction

Strong CYP3A4 Inhibitors

  • Reduce the ZURZUVAE dosage when used with a strong CYP3A4 inhibitor

CYP3A4 Inducers

  • Avoid concomitant use of ZURZUVAE with CYP3A4 inducers
 

USE IN SPECIFIC POPULATIONS

Pregnancy

  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including ZURZUVAE, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/
  • Based on findings from animal studies, ZURZUVAE may cause fetal harm. Advise pregnant women of the potential risk to a fetus. Available data on ZURZUVAE use in pregnant women from the clinical development program are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Lactation

  • Available data from a clinical lactation study in 14 women indicate that zuranolone is present in low levels in human milk. There are no data on the effects of zuranolone on a breastfed infant and limited data on the effects on milk production
  • The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZURZUVAE and any potential adverse effects on the breastfed child from ZURZUVAE or from the underlying maternal condition

Hepatic Impairment

  • The recommended ZURZUVAE dosage in patients with severe hepatic impairment (Child-Pugh C) is lower than patients with normal hepatic function

Renal Impairment

  • The recommended ZURZUVAE dosage in patients with moderate and severe renal impairment is lower than those with normal renal function
 

DRUG ABUSE AND DEPENDENCE

  • ZURZUVAE contains zuranolone, a Schedule IV controlled substance
  • Zuranolone has abuse potential with associated risks of misuse, abuse, and substance use disorder including addiction
  • ZURZUVAE may produce physical dependence
 

Please see full Prescribing Information, including Boxed Warning.

Terms of Use Notice to CA Residents Privacy Policy Contact Us Cookie Policy Unsubscribe Pricing Disclosures

This site is intended for US healthcare professionals.

ZURZUVAE and the ZURZUVAE logo are trademarks of Sage Therapeutics licensed to Supernus Pharmaceuticals, Inc. BIOGEN and the BIOGEN logo are registered trademarks of Biogen Inc. SUPERNUS PHARMACEUTICALS and the SUPERNUS PHARMACEUTICALS logo are registered trademarks of Supernus Pharmaceuticals, Inc. All other trademarks referenced herein are the property of their respective owners.

©2026 Supernus Pharmaceuticals, Inc. All rights reserved.


©2026 Biogen. All rights reserved. ZUR-US-0299v7 04/26